453 related articles for article (PubMed ID: 32449514)
21. Adrenocortical carcinoma.
Baudin E;
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
[TBL] [Abstract][Full Text] [Related]
23. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
[TBL] [Abstract][Full Text] [Related]
24. Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma.
Lacombe AMF; Soares IC; Mariani BMP; Nishi MY; Bezerra-Neto JE; Charchar HDS; Brondani VB; Tanno F; Srougi V; Chambo JL; Costa de Freitas RM; Mendonca BB; Hoff AO; Almeida MQ; Weigand I; Kroiss M; Zerbini MCN; Fragoso MCBV
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963898
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
26. National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?
Tierney JF; Chivukula SV; Poirier J; Pappas SG; Schadde E; Hertl M; Kebebew E; Keutgen X
J Clin Endocrinol Metab; 2019 Dec; 104(12):5948-5956. PubMed ID: 31361313
[TBL] [Abstract][Full Text] [Related]
27. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Tang Y; Liu Z; Zou Z; Liang J; Lu Y; Zhu Y
Biomed Res Int; 2018; 2018():9362108. PubMed ID: 29967789
[TBL] [Abstract][Full Text] [Related]
28. A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
Khan MS; Ali A; Tariq I; Khan MA; Bakar MA; Anwar AW
J Pak Med Assoc; 2019 May; 69(5):717-719. PubMed ID: 31105294
[TBL] [Abstract][Full Text] [Related]
29. Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience.
Pan LH; Yen CC; Huang CJ; Ng XN; Lin LY
Front Endocrinol (Lausanne); 2023; 14():1134643. PubMed ID: 36967802
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
[TBL] [Abstract][Full Text] [Related]
31. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
32. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
Smith DC; Kroiss M; Kebebew E; Habra MA; Chugh R; Schneider BJ; Fassnacht M; Jafarinasabian P; Ijzerman MM; Lin VH; Mohideen P; Naing A
Invest New Drugs; 2020 Oct; 38(5):1421-1429. PubMed ID: 31984451
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Adrenocortical Carcinoma.
Vaidya A; Nehs M; Kilbridge K
Surg Pathol Clin; 2019 Dec; 12(4):997-1006. PubMed ID: 31672303
[TBL] [Abstract][Full Text] [Related]
34. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
Kroiss M; Sbiera S; Kendl S; Kurlbaum M; Fassnacht M
Horm Cancer; 2016 Dec; 7(5-6):345-355. PubMed ID: 27631436
[TBL] [Abstract][Full Text] [Related]
35. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.
Puglisi S; Perotti P; Cosentini D; Roca E; Basile V; Berruti A; Terzolo M
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1125-1133. PubMed ID: 30117750
[TBL] [Abstract][Full Text] [Related]
36. Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M; Zaggia B; Allasino B; De Francia S
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
[TBL] [Abstract][Full Text] [Related]
37. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
38. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series.
Kostiainen I; Hakaste L; Kejo P; Parviainen H; Laine T; Löyttyniemi E; Pennanen M; Arola J; Haglund C; Heiskanen I; Schalin-Jäntti C
Endocrine; 2019 Jul; 65(1):166-174. PubMed ID: 30980285
[TBL] [Abstract][Full Text] [Related]
39. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
40. Surgical management of adrenocortical carcinoma.
Ranvier GG; Inabnet WB
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]